Akari Therapeutics, Plc (AKTX)
NASDAQ: AKTX · Real-Time Price · USD
1.090
0.00 (0.02%)
Jul 16, 2025, 10:30 AM - Market open

Akari Therapeutics, Stock Forecast

Stock Price Forecast

There is currently no analyst price target forecast available for Akari Therapeutics,.

Price Target: n/a
Analyst Consensus: n/a
TargetLowAverageMedianHigh
Pricen/an/an/an/a
Changen/an/an/an/a

Analyst Ratings

There are currently no analyst ratings available for Akari Therapeutics,.

Recommendation Trends

RatingJul '22Aug '22Sep '22Oct '22Nov '22Dec '22
Strong Buy111110
Buy000000
Hold000000
Sell000000
Strong Sell000000
Total111110

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Initiates
$30
Strong BuyInitiates$30+2,652.29%Dec 5, 2022
Alliance Global Partners
Alliance Global Partners
Strong Buy
Initiates
$80
Strong BuyInitiates$80+7,239.45%Nov 1, 2022
B. Riley Securities
B. Riley Securities
Strong Buy
Maintains
$140$100
Strong BuyMaintains$140$100+9,074.31%Mar 13, 2020
Canaccord Genuity
Canaccord Genuity
Strong Buy
Maintains
$300$160
Strong BuyMaintains$300$160+14,578.90%Mar 29, 2018
B. Riley Securities
B. Riley Securities
Hold
Initiates
$60
HoldInitiates$60+5,404.59%Feb 8, 2018
More Analyst Ratings

Financial Forecast

Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.46
from -1.66
EPS Next Year
-0.41
from -0.46
Fiscal YearFY 2020FY 2021FY 2022FY 2023FY 2024FY 2025FY 2026FY 2027
Period EndingDec 31, 2020Dec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026Dec 31, 2027
Revenue
4.28M--
Revenue Growth
--------
EPS
-20.00-8.12-5.69-2.04-1.66-0.46-0.41-0.46
EPS Growth
--------
Forward PE
--------
No. Analysts
-----333
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue2025
High4.4M
Avg4.3M
Low4.1M

Revenue Growth

Revenue Growth2025
High-
Avg-
Low-

EPS Forecast

EPS202520262027
High-0.47-0.42-0.47
Avg-0.46-0.41-0.46
Low-0.44-0.39-0.44

EPS Growth

EPS Growth202520262027
High---
Avg---
Low---
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.